AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
nemonapride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sulpiride derivatives and analogues | 1895 | 75272-39-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an atypical antipsychotic approved in Japan for the treatment of schizophrenia
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,TEK,TTK | 29 | |||
| kinase-selectivity-class | AKT3,AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,SIK2,SIK3,TEK | 10 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.07 | acidic |
| pKa2 | 7.63 | Basic |
| pKa3 | 3.08 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | Ki | 8.58 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.30 | IUPHAR | ||||
| D(4) dopamine receptor | GPCR | Kd | 9.68 | CHEMBL | |||||
| Transmembrane protein 97 | Enzyme | Ki | 8.14 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 6.27 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 9.80 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 7.31 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01468 | KEGG_DRUG |
| C0217937 | UMLSCUI |
| CHEBI:31899 | CHEBI |
| AQD | PDB_CHEM_ID |
| CHEMBL20734 | ChEMBL_ID |
| C030265 | MESH_SUPPLEMENTAL_RECORD_UI |
| 156333 | PUBCHEM_CID |
| 983 | IUPHAR_LIGAND_ID |
| 6430 | INN_ID |
| Q88T5P3444 | UNII |
| Q88T5P3444 | INXIGHT DRUGS |
Pharmaceutical products:
None